Skip to content

Released Nov 14, 2022, before the open

10-Q filed Nov 14, 2022, 45 days after period end · 0001558370-22-017554

Q3 2022 · 10-Q
Revenue$14.18M+17.7% vs Q3 2021+62.0% vs Q2 2022
Net Income-$3.57MN/M vs Q3 2021N/M vs Q2 2022
EPS Diluted-$0.07N/M vs Q3 2021N/M vs Q2 2022
Operating Income-$3,125,000N/M
Operating Cash Flowderived-$9,204,000N/M
Free Cash Flowderived-$9,262,000N/M
Margins · derived
Operating margin-22.0%−6.4 pt vs Q3 2021
Net margin-25.1%+9.7 pt vs Q3 2021

What the release said

The release

Same quarter

MetricQ3 2022Q3 2021Q3 2020Q3 2019
Revenue$14.18M$12.05M$10.79M$14.25M
Net Income-$3.57M-$4.20M-$4.44M-$3.56M
EPS Diluted-$0.07-$0.09-$0.14-$0.24

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR